Press Releases May 13, 2026 04:05 PM

Brilliant Earth Announces Participation in Upcoming Investor Conferences

Brilliant Earth to Participate in Key Investor Conferences in May and June 2026

By Avery Klein
Share
Twitter Reddit Facebook LinkedIn
BRLT

Brilliant Earth Group, Inc., a leader in ethically sourced fine jewelry, announced its participation in the B. Riley Securities Annual Investor Conference and the TD Cowen 10th Annual Future of the Consumer Conference. The company will engage with investors through meetings and a fireside chat webcast. With a mission focused on transparency and sustainability, the company reported $437 million in net sales for 2025 and continues expanding its U.S. showroom presence and global customer base.

Brilliant Earth Announces Participation in Upcoming Investor Conferences
BRLT
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Brilliant Earth will attend two major investor conferences in 2026 to engage with investors and present its business outlook.
  • The company emphasizes its mission of ethics, sustainability, and transparency in the fine jewelry industry.
  • Brilliant Earth reported net sales of $437 million for 2025 and has 42 showrooms across the United States, serving customers in over 50 countries.

SAN FRANCISCO, May 13, 2026 (GLOBE NEWSWIRE) -- Brilliant Earth Group, Inc. (“Brilliant Earth” or the “Company”) (NASDAQ: BRLT), an innovative, global leader in ethically sourced fine jewelry, today announced that the Company will participate in upcoming investor events.

On May 21, 2026, the Company will participate in the B. Riley Securities Annual Investor Conference being held at the Ritz-Carlton, Marina Del Rey in Marina Del Rey, California, and will meet with investors throughout the day.

On June 2, 2026, the Company will participate in the TD Cowen 10th Annual Future of the Consumer Conference being held at the Lotte New York Palace in New York, New York. Management will host a fireside chat at 11:00am ET and meet with investors throughout the day.

A live webcast of this fireside chat can be accessed here or at the “Events and Presentations” section of Brilliant Earth’s investor website at Events | Brilliant Earth Group, Inc.  An archived replay will be available on the Company’s Investor Relations Website and will remain available for one year following the live event. 

About Brilliant Earth 
Brilliant Earth is an industry-disrupting global leader in ethically sourced fine jewelry.  The Company's mission since its founding in 2005 has been to create a more transparent, sustainable, and compassionate jewelry industry. With a premium brand, curated proprietary product assortment, seamless omnichannel shopping experience, and asset-light, data driven business model, Brilliant Earth is transforming the jewelry industry. The Company reported Net Sales of $437 million for the full year 2025. Headquartered in San Francisco, CA, Brilliant Earth has 42 showrooms and counting across the United States and has served customers in over 50 countries worldwide.   

Contacts:

Investor Relations:
Colin Bourland
investorrelations@brilliantearth.com


Risks

  • Investor response to conference presentations and future outlook is uncertain and could affect stock performance.
  • The luxury and consumer discretionary sectors could be impacted by economic fluctuations affecting consumer demand for fine jewelry.
  • Continued growth and scaling risks exist, including maintaining product quality and sourcing ethics while expanding showroom footprint and international operations.

More from Press Releases

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026 Jun 14, 2026 Mineralys Therapeutics Presents Late-Breaking Data on Lorundrostat and Heart Failure Risk Biomarkers at The Endocrine Society Annual Meeting (ENDO 2026) Jun 14, 2026 Celldex Presents Positive First-in-Human Results from Phase 1 Study of Novel Bispecific CDX-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting Jun 14, 2026 Legend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Jun 14, 2026